Related Experiment Video

Updated: May 16, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

EMA601 and glenzocimab: two glycoprotein VI inhibitory Fabs with different potency

Bernhard Nieswandt1,2, David Stegner1,2, Stefano Navarro1,2

  • 1Institute of Experimental Biomedicine I, Würzburg Josef-Schneider-Straße 2, 97080 Würzburg, Germany.

European Heart Journal
|April 2, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
08:58

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques

Published on: July 5, 2018

12.5K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.7K

Related Experiment Videos

Last Updated: May 16, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
08:58

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques

Published on: July 5, 2018

12.5K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.7K

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K

Articles linked to this work by shared authors, journal, and citation graph.

Partial downregulation of platelet glycoprotein VI by low affinity antibodies confers sustained and safe antithrombotic protection.

Signal transduction and targeted therapy·2026

Blocking microglial reactivity via purinergic receptors prevents subacute cognitive deficits after TIA.

EMBO molecular medicine·2026

Thrombo-inflammatory endothelial signatures in JAK2 -mutated myeloproliferative neoplasms.

bioRxiv : the preprint server for biology·2026

Platelet-derived integrin- and tetraspanin-enriched tethers exacerbate severe inflammation.

Science (New York, N.Y.)·2026

Platelet Casein Kinase 2α is a pivotal player in arterial thrombotic occlusion and post-ischemic myocardial remodeling.

Cardiovascular research·2026

Platelets drive macrophage inflammatory activation in vitro.

Journal of leukocyte biology·2025

Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis.

European heart journal·2026

Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis.

European heart journal·2026

Safety of withdrawal of pharmacological treatment after recovery from HER2 therapy-related cardiac dysfunction: the HER-SAFE trial.

European heart journal·2026

Clonal haematopoiesis and cardiovascular-kidney-metabolic syndrome: a cohort study.

European heart journal·2026

Increasing plasma potassium and risk of atrial fibrillation: the POTCAST trial.

European heart journal·2026

Adrenomedullin system dysregulation predicts cardiogenic shock and mortality in acute coronary syndromes.

European heart journal·2026

Multisystem Benefits of GLP-1 Microdosing: A Narrative Review.

Cureus·2026

Granulomatous Interstitial Nephritis With Perivascular Involvement in Carbamazepine-Induced DRESS Syndrome: A Case Report.

Kidney medicine·2026

Additive effect of Ruta graveolens bioactive phytoconstituents and cisplatin through PKC/MEK/ERK pathway in glioblastoma.

Molecular therapy. Oncology·2026

Challenges and approaches to the design of hydrophilic linkers for antibody-drug conjugates.

Journal of controlled release : official journal of the Controlled Release Society·2026

Dissecting Cellulitis and Hidradenitis Suppurativa: Two Diseases or One Follicular-Occlusion Spectrum?

International journal of dermatology·2026

Effect of sugar modifications on the solution stability of nucleoside phosphoramidites.

Nucleosides, nucleotides & nucleic acids·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us